[{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Isu Abxis, Ranked First for Two Consecutive Years in the Algerian Gaucher Disease Treatment Bidding","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Isu Abxis Expects 100% Exclusive Treatment for Gaucher Disease in Algeria","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals for Imiglucerase
Abcertin (Imiglucerase) is an orphan drug independently developed by Isu Abxis, is an Enzyme Replacement Therapy (ERT) treatment for Gaucher disease with the same ingredient name as Cerezyme.
Abcertin (Imiglucerase) is an orphan drug independently developed by Isu Abxis, is an Enzyme Replacement Therapy (ERT) treatment for Gaucher disease with the same ingredient name as Cerezyme.